Total Assets (Quarterly) Chart

View Total Assets (Quarterly) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Assets (Quarterly) Chart
Start Trial

Historical Total Assets (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 41.73B
March 31, 2026 40.87B
December 31, 2025 40.56B
September 30, 2025 40.17B
June 30, 2025 38.22B
March 31, 2025 37.55B
December 31, 2024 37.85B
September 30, 2024 37.44B
June 30, 2024 36.09B
March 31, 2024 34.37B
December 31, 2023 33.13B
September 30, 2023 32.16B
June 30, 2023 30.66B
March 31, 2023 30.06B
December 31, 2022 29.27B
September 30, 2022 27.68B
June 30, 2022 27.21B
March 31, 2022 26.35B
December 31, 2021 25.43B
September 30, 2021 23.67B
June 30, 2021 21.49B
March 31, 2021 17.77B
December 31, 2020 17.16B
September 30, 2020 16.08B
June 30, 2020 14.43B
Date Value
March 31, 2020 15.76B
December 31, 2019 14.81B
September 30, 2019 13.94B
June 30, 2019 13.17B
March 31, 2019 12.85B
December 31, 2018 11.73B
September 30, 2018 10.81B
June 30, 2018 9.952B
March 31, 2018 9.373B
December 31, 2017 8.812B
September 30, 2017 8.701B
June 30, 2017 8.106B
March 31, 2017 7.817B
December 31, 2016 6.983B
September 30, 2016 6.828B
June 30, 2016 6.205B
March 31, 2016 5.904B
December 31, 2015 5.630B
September 30, 2015 5.183B
June 30, 2015 4.527B
March 31, 2015 4.199B
December 31, 2014 3.872B
September 30, 2014 3.739B
June 30, 2014 3.456B
March 31, 2014 3.260B

Total Assets Definition

Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.

Read full definition.

Total Assets (Quarterly) Range, Past 5 Years

View Total Assets (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Assets (Quarterly) Benchmarks

View Total Assets (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 5.559B
Gilead Sciences, Inc. 49.36B
AbbVie, Inc. 135.12B
Vertex Pharmaceuticals, Inc. 27.42B
Amgen, Inc. 95.64B

Total Assets (Quarterly) Related Metrics